neurochemical markers in cerebrospinal fluid of patients with dementia

1
BioMed Central Page 1 of 1 (page number not for citation purposes) Annals of General Psychiatry Open Access Oral presentation Neurochemical markers in cerebrospinal fluid of patients with dementia George Paraskevas* Address: Department of Neurology, Eginition Hospital, Athens University Medical School, Athens Greece * Corresponding author The presence of a long history of alcohol abuse in patients with cognitive decline may be a problem in the differen- tial diagnosis, especially when dealing with elderly patients, where Alzheimer's disease (AD) is the most fre- quent cause of dementia. Since specific treatments are now available for AD, while the effect of alcohol on cog- nition may be reversible to some extent, the need for early discrimination between the two disorders is obvious. Cerebrospinal fluid (CSF) markers including tau protein, amyloid Aβ42 and their ratio received much attention recently, since they may be of some help in the diagnosis of AD and the differential diagnosis from other causes of dementia, in terms of every-day practice. In the differen- tial diagnosis of AD from alcohol-related cognitive decline CSF tau is better than Aβ42 alone. In a patient with cognitive decline and history of alcohol abuse increased levels of CSF tau almost confirm the (co)exist- ence of AD at all levels of clinical confidence. However, normal CSF tau levels do not always exclude AD. The combined use of tau with Aβ42 in the form of their ratio (tau/Aβ42) resolves the problem. An increased ratio almost confirms the (co)existence of AD, with a positive predictive value that may approach or even exceed 99% at all levels of clinical (pre-test) confidence, while a normal ratio almost excludes the (co)existence of AD, with a neg- ative predictive value > 90% at all levels of clinical confi- dence. The discriminating value is comparable in patient with early cognitive decline (MMSE > 23) or more advanced disease. The method required for the determination of tau and Aβ42 is an ELISA method, which is easy to perform and does not require ionizing radiation, specially trained per- sonnel and expensive equipment. Lumbar puncture is a minimally to moderately invasive procedure, but usually well tolerated and safe, provided that there is no contrain- dication. The incidence of post-lumbar puncture head- ache is low in the elderly population and probably no more than 5.5%. Given the above, the determination of CSF markers of AD may be helpful in the every-day diag- nostic work-up of elderly demented patients with a his- tory of alcohol abuse. from International Society on Brain and Behaviour: 2nd International Congress on Brain and Behaviour Thessaloniki, Greece. 17–20 November 2005 Published: 28 February 2006 Annals of General Psychiatry 2006, 5(Suppl 1):S58 doi:10.1186/1744-859X-5-S1-S58 <supplement> <title> <p>International Society on Brain and Behaviour: 2nd International Congress on Brain and Behaviour</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcen- tral.com/content/files/pdf/1744-859X-5-S1-full.pdf">here</a>.</note> </supplement>

Upload: george-paraskevas

Post on 06-Jul-2016

224 views

Category:

Documents


3 download

TRANSCRIPT

Page 1: Neurochemical markers in cerebrospinal fluid of patients with dementia

BioMed Central

Page 1 of 1(page number not for citation purposes)

Annals of General Psychiatry

Open AccessOral presentationNeurochemical markers in cerebrospinal fluid of patients with dementiaGeorge Paraskevas*

Address: Department of Neurology, Eginition Hospital, Athens University Medical School, Athens Greece

* Corresponding author

The presence of a long history of alcohol abuse in patientswith cognitive decline may be a problem in the differen-tial diagnosis, especially when dealing with elderlypatients, where Alzheimer's disease (AD) is the most fre-quent cause of dementia. Since specific treatments arenow available for AD, while the effect of alcohol on cog-nition may be reversible to some extent, the need for earlydiscrimination between the two disorders is obvious.

Cerebrospinal fluid (CSF) markers including tau protein,amyloid Aβ42 and their ratio received much attentionrecently, since they may be of some help in the diagnosisof AD and the differential diagnosis from other causes ofdementia, in terms of every-day practice. In the differen-tial diagnosis of AD from alcohol-related cognitivedecline CSF tau is better than Aβ42 alone. In a patientwith cognitive decline and history of alcohol abuseincreased levels of CSF tau almost confirm the (co)exist-ence of AD at all levels of clinical confidence. However,normal CSF tau levels do not always exclude AD. Thecombined use of tau with Aβ42 in the form of their ratio(tau/Aβ42) resolves the problem. An increased ratioalmost confirms the (co)existence of AD, with a positivepredictive value that may approach or even exceed 99% atall levels of clinical (pre-test) confidence, while a normalratio almost excludes the (co)existence of AD, with a neg-ative predictive value > 90% at all levels of clinical confi-dence. The discriminating value is comparable in patientwith early cognitive decline (MMSE > 23) or moreadvanced disease.

The method required for the determination of tau andAβ42 is an ELISA method, which is easy to perform anddoes not require ionizing radiation, specially trained per-sonnel and expensive equipment. Lumbar puncture is aminimally to moderately invasive procedure, but usually

well tolerated and safe, provided that there is no contrain-dication. The incidence of post-lumbar puncture head-ache is low in the elderly population and probably nomore than 5.5%. Given the above, the determination ofCSF markers of AD may be helpful in the every-day diag-nostic work-up of elderly demented patients with a his-tory of alcohol abuse.

from International Society on Brain and Behaviour: 2nd International Congress on Brain and BehaviourThessaloniki, Greece. 17–20 November 2005

Published: 28 February 2006

Annals of General Psychiatry 2006, 5(Suppl 1):S58 doi:10.1186/1744-859X-5-S1-S58<supplement> <title> <p>International Society on Brain and Behaviour: 2nd International Congress on Brain and Behaviour</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcen-tral.com/content/files/pdf/1744-859X-5-S1-full.pdf">here</a>.</note> </supplement>